140 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
research and development programs. Underscores our commitment to patients. Reflects our objective of driving commercial revenue success, driving
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
, and technology—including AI—across our research and development capabilities, we are finding ways to discover, develop and deliver innovative medicines
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
and in-license agreements with third parties for products and compounds for research and development projects. Payments for collaboration agreements generally take … of a product in development, the related in-process research and development assets will be reclassified to intangible assets associated with marketed
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:24am
years 8/8 (100%) 2 Andrew Plump To be reelected Director President, Research and Development 9 years 8/8 (100%) 3 Milano Furuta To be newly elected … Director of the Company (to present) June 2015 Chief Medical & Scientific Officer of the Company January 2019 President, Research & Development
6-K
TAK
Takeda Pharmaceutical Co
9 May 24
Current report (foreign)
6:01am
, engaged primarily in the research, development, production and global commercialization of pharmaceutical products. Takeda focuses on six key business … fiscal year
AER
CER
Amount of Change
% Change
Revenue
Cost of sales
Selling, general and administrative expenses
Research and development expenses
6-K
w2yqhtptc2ayemjwg
2 Feb 24
Current report (foreign)
6:16am
6-K
x1nk6 hd72fof
1 Feb 24
Current report (foreign)
6:06am
6-K
ovysemjups299q8 dtjo
16 Jan 24
Current report (foreign)
6:01am
6-K
EX-99.1
wls0kfr
14 Dec 23
Current report (foreign)
6:01am
6-K
EX-99.1
0uusftjw
30 Nov 23
Current report (foreign)
6:01am
6-K
y90x4hw9
30 Oct 23
Current report (foreign)
6:02am
6-K
5t0oasu8q12tf
26 Oct 23
Current report (foreign)
6:20am
6-K
y2oj 1zy2qe45h
1 Aug 23
Current report (foreign)
6:10am
6-K
qalgelpy9ot
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
nq83jbvriaqk33
12 Jul 23
Current report (foreign)
6:07am
144
83y6rmngjdgnr8cmn
10 Jul 23
Notice of proposed sale of securities
6:09am
6-K
EX-99.1
y5o vxrire
6 Jul 23
Current report (foreign)
6:18am
S-8
racmwqqm49ojxjdaeq
28 Jun 23
Registration of securities for employees
6:35am
6-K
EX-99.1
z13rz7bond5y
23 Jun 23
Current report (foreign)
6:13am